Roivant Sciences Ltd.
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophos…
Biotechnology
GB, London [HQ]
Ratios
5 Sheets · Starting from 2023Margins, Growth Rates In %
| Ratio | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross Margin | 73.92 | 98.33 | 91.36 | 83.78 | 78.58 | |
| Profit Margin | -44,835.15 | 1,773.57 | -3,783.29 | -1,671.52 | -2,007.22 | |
| Operating Margin | -32,206.97 | -786.58 | -4,500.52 | -2,191.78 | -1,758.44 | |
|
EPS Growth
|
- - | 215.08 | -172.53 | 65.84 | -25.36 | |
| EPS USD | -484.00 | 557.00 | -404.00 | -138.00 | -173.00 | |
| Return on Assets (ROA) | -75.08 | 48.47 | -34.76 | -35.75 | -51.47 | |
| Return on Equity (ROE) | -145.33 | 59.08 | -50.07 | -45.32 | -76.51 | |
| Return on Invested Capital (ROIC) | -87.30 | -25.09 | -52.52 | -52.19 | -51.80 | |
| Solvency | ||||||
| Equity Ratio | - - | - - | - - | - - | - - | |
| Debt/Assets | 10.32 | 4.70 | 9.46 | 10.98 | 20.15 | |
| Debt/Equity | 19.97 | 5.73 | 13.63 | 13.92 | 29.95 | |
| Debt/EBITDA | -511.40 | -2,390.55 | 354.57 | 118.45 | 107.93 | |
|
Debt/Capitalization
|
16.65 | 5.42 | 11.99 | 12.22 | 23.04 | |
| Long-Term Debt/Capitalization | 14.54 | 5.07 | 11.46 | 11.79 | 21.06 | |
| Interest Debt per Share USD | 0.70 | 0.58 | 1.11 | 0.43 | 0.71 | |
| Debt Growth | - - | 26.34 | 35.43 | 15.89 | 69.57 | |
| Liquidity | ||||||
| Current Ratio | 561.12 | 2,409.13 | 998.81 | 1,164.27 | 660.16 | |
| Quick Ratio | 407.31 | 2,389.07 | 944.86 | 1,128.60 | 633.09 | |
| Cash Ratio | 402.12 | 2,372.48 | 938.54 | 1,117.55 | 615.46 | |
| Operating Cash Flow Ratio | -400 | -800 | -200 | -300 | -300 | |
| Turnover | ||||||
| Inventory Turnover | - - | - - | 3.22 | -54.46 | 475.48 | |
| Receivables Turnover | 21.19 | 443.02 | 172.03 | 821.24 | 187.20 | |
| Payables Turnover | 9.72 | 10.97 | 10.01 | 25.93 | 34.70 | |
|
Asset Turnover
|
0.17 | 2.73 | 0.92 | 2.14 | 2.56 | |
| Fixed Turnover | 20.92 | 91.56 | 30.89 | 63.58 | 66.37 | |
| Coverage | ||||||
| Interest Coverage | -9,932.19 | -6,929.91 | -38,123.82 | -17,209.88 | -3,852.86 | |
| Asset Coverage | 800 | 1,300 | 900 | 800 | 400 | |
| Cash Flow Coverage (CFGR) | -715.36 | -654.32 | -225.38 | -238.73 | -175.19 | |
| EBITDA Coverage | 1,800 | 1,000 | -18,100 | -21,300 | -3,900 | |
| Dividend Coverage | - - | - - | - - | - - | - - | |
| Time Interest Earned (TIE) | - - | - - | - - | - - | - - | |
| Market Prospects | ||||||
| Dividend Yield | - - | - - | - - | - - | - - | |
| Earnings Yield | -46.52 | 53.60 | -41.34 | -27.93 | -23.38 | |
|
Price/Earnings (P/E)
|
-214.95 | 186.56 | -241.91 | -358.03 | -427.67 | |
| Price/Earnings Growth (PEG) | - - | -0.87 | 1.40 | 5.44 | -16.86 | |
|
Price/Book (P/B)
|
312.39 | 110.21 | 121.13 | 162.27 | 327.22 | |
| Price/Tangible Book (P/TB) | 312.39 | 110.21 | 121.13 | 162.27 | 327.22 | |
| Price/Sales (P/S) | 96,371.49 | 3,308.77 | 9,151.97 | 5,984.48 | 8,584.20 | |
|
Price/Cash Flow (P/CF)
|
-218.67 | -293.99 | -394.41 | -488.19 | -623.72 | |
| Price/Free CF (P/FCF) | -216.26 | -292.10 | -390.31 | -475.94 | -614.47 | |
| Price/Operating CF (P/OCF) | -218.67 | -293.99 | -394.41 | -488.19 | -623.72 |